All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Octapharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients

Contact the Supplier

Lead Product(s): Human Immune Globulin

Therapeutic Area: Infections and Infectious Diseases Product Name: Octagam

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group.

Octapharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Octapharma USA Extends Funding for COVID-19 Study Following Positive Preliminary Research Data

Contact the Supplier

Lead Product(s): Human Immune Globulin

Therapeutic Area: Infections and Infectious Diseases Product Name: Octagam

Highest Development Status: Phase IV Product Type: Large molecule

Partner/Sponsor/Collaborator: University of California San Diego School of Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding June 03, 2020

Details:

The randomized open label study is evaluating the standard of care (SOC) plus intravenous immunoglobulin (IVIG) compared to SOC alone in the treatment of COVID-19 infection, specifically in preventing mechanical ventilation in COVID-19 patients requiring high-flow oxygen.